Stoke Therapeutics (NASDAQ:STOK) Insider Jason Hoitt Sells 1,781 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Jason Hoitt sold 1,781 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $33.01, for a total transaction of $58,790.81. Following the transaction, the insider owned 12,207 shares of the company’s stock, valued at approximately $402,953.07. This trade represents a 12.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Jason Hoitt also recently made the following trade(s):

• On Wednesday, March 18th, Jason Hoitt sold 1,931 shares of Stoke Therapeutics stock. The stock was sold at an average price of $31.34, for a total value of $60,517.54.

Stoke Therapeutics Trading Up 7.0%

NASDAQ:STOK traded up $2.17 during trading hours on Thursday, hitting $33.19. 853,428 shares of the stock were exchanged, compared to its average volume of 754,489. The firm’s fifty day moving average price is $32.61 and its 200 day moving average price is $29.90. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $40.22. The company has a market cap of $1.96 billion, a P/E ratio of 49.54 and a beta of 1.07.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new position in Stoke Therapeutics during the fourth quarter worth $26,000. Harbour Investments Inc. raised its holdings in shares of Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares during the period. Generali Investments Management Co LLC acquired a new position in Stoke Therapeutics during the 3rd quarter worth about $41,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Stoke Therapeutics by 31.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after acquiring an additional 658 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after acquiring an additional 1,668 shares during the period.

Analysts Set New Price Targets

Several brokerages have issued reports on STOK. UBS Group set a $50.00 target price on shares of Stoke Therapeutics in a research note on Monday, December 15th. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a research note on Monday, January 5th. HC Wainwright boosted their price target on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Needham & Company LLC increased their price objective on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday. Finally, BTIG Research reissued a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.83.

Stoke Therapeutics News Roundup

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Multiple analysts raised or reiterated bullish ratings and price targets this week (BTIG reaffirmed “buy” with a $39 target; Wedbush lifted its target to $38; Needham raised its target toward $40 and Chardan keeps a $35 target) — these actions increase buy-side interest and provide technical/supportive buying. Read More.
• Positive Sentiment: Pipeline story: coverage highlighting STK‑001’s potential to restore developmental deficits in Dravet syndrome (beyond seizure control) supports upside for long-term clinical value if trials continue to show benefit. Read More.
• Neutral Sentiment: Company granted inducement stock options to new hires — helps recruiting but adds potential future dilution; not an immediate earnings impact. Read More.
• Negative Sentiment: Quarterly results missed expectations: EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.3M expected — the earnings/revenue shortfall is the clearest near-term driver of prior downward pressure and investor concern about near-term commercialization/visibility. Read More.
• Negative Sentiment: Insider sale disclosed — Director Arthur A. Levin sold 605 shares (~$22k) in mid‑March; small in dollar terms but sometimes interpreted as a mild negative signal by short‑term traders. Read More.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.